DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Conversion From Fast Acting Oral Opioids to Abstral®

Information source: Orexo AB
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Pain

Intervention: SL fentanyl (Drug)

Phase: Phase 4

Status: Suspended

Sponsored by: Orexo AB

Official(s) and/or principal investigator(s):
Anders Pettersson, MD, PhD, Study Chair, Affiliation: Orexo AB

Summary

The purpose of this study is to evaluate safety and efficacy when using a novel dose conversion strategy to switch from immediate release oral opioids to sublingual (SL) fentanyl (Abstral) for treatment of breakthrough cancer pain (BTcP).

Clinical Details

Official title: Conversion From Fast Acting Oral Opioids to Abstral (SL Fentanyl) in Opioid Tolerant Cancer Patients With Breakthrough Pain

Study design: Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Response rate in patients converted to SL fentanyl.

Secondary outcome:

Responder rate in patients converted to SL fentanyl as assessed by the PID15.

Edmonton Symptom Assessment System (ESAS) Symptom Distress Score (SDS)

Patient's global assessment of treatment (patient satisfaction).

Patients preference of treatment (baseline treatment/SL fentanyl).

Occurrence of AEs, withdrawals

Detailed description: The study aims to show that in the advanced stage of cancer the individual patient already on high doses of BTcP medication will benefit from starting treatment on a higher first dose of SL fentanyl thus reducing the number of dosing steps with insufficient pain relief.

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Signed informed consent obtained.

- 18 years or older, of both genders.

- Opioid tolerant patients

- Estimated frequency of BTcP 0. 5-4 times a day.

Exclusion Criteria:

- Treatment with SL fentanyl within two weeks prior to screening.

- Recent or planned therapy that would alter pain or responses to analgesics.

- Treatment with monoamine oxidase inhibitor < 14 days before or concurrent with SL

fentanyl treatment.

- Significantly reduced liver and/or kidney function.

- Significant prior history of substance abuse.

- Pregnancy, breast feeding or woman of childbearing potential not using adequate

birth control.

Locations and Contacts

Smärtavdelning B42, Anestesikliniken Karolinska University Hospital, Huddinge, Stockholm SE-141 86, Sweden
Additional Information

Starting date: February 2011
Last updated: June 19, 2012

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017